Best Practices and Research Advances in Thoracic Oncology: A Regional Series SE Asia Course 3: Driver Alterations in Lung Cancer

This activity provides learners from the SE Asia Region with an overview of how to best utilize driver alterations in the diagnosis and treatment of lung cancer.

Course 3: Driver Alterations in Lung Cancer

Targeted Therapies in Advanced Disease

Adjuvant Treatment from EGFR to Other Biomarkers

KRAS the New (Old) Kid on the Block

Brain Metastasis in Driver Alterations with Clinical Case

Molecular Profiling: Research and Networking in the region

Molecular Profiling in the Region: Opportunities and Challenges

Enduring Activity Launch Date: February 28, 2025
Enduring Activity Expiration Date: February 28, 2026

This activity is designed for multidisciplinary teams of medical oncologists, surgical oncologists, pathologists, histologists, clinical radiation oncologists, pulmonologists, radiologists and interventional radiologists, translational scientists, nurses, nurse practitioners, scientists, specialty pharmacists and physician associates within SE Asia.

Upon completion of this educational activity, participants should be able to:

Describe how liquid biopsy can be utilized to assist in determining the appropriate management for patients with thoracic malignancies

Discuss the role of immunotherapy across all stages of lung cancer

Review the current treatments for patients with oncogenic driven lung cancer

This activity is supported by an independent educational grant from AstraZeneca.

Co-Chairs:

Christian Rolfo, MD, PhD, MBA, Dr.hc. The Arthur G. James Comprehensive Cancer Center, USA

Ross Soo, MD, National University Hospital, Singapore

Presenters:

Charu Aggarwal, MD, MPH, FASCO, University of Pennsylvania, USA

Koichi Goto, MD, PhD, National Cancer Center Hospital East, Chiba, Japan

Rina Hui, MBBS, PhD, University of Hong Kong ,Hong Kong, China

Puneeth Iyengar, MD, PhD, UT Southwestern Medical Center, Dallas, Texas

Sun Min Lim, MD, PhD, Yonsei University College of Medicine, Seoul, Republic of Korea

Benjamin Solomon, MBBS, PhD, FRACP, FAHMS, Peter MacCallum Cancer Centre, Melbourne, Australia

Junko Tanizaki, MD, PhD, Kindai University, Osaka, Japan

Yasushi Yatabe, MD, PhD, National Cancer Center Japan, Tokyo, Japan

The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose:

Full Legal Name	Commercial Interest	Role	Level of Participation in the Activity
Charu Aggarwal	Daiichi Sankyo/AstraZeneca - To Institution, Merck sharp & Dohme - To Institution, AstraZeneca/MedImmune -To Institution, Loxo@Lilly- To Institution, Candel Therapeutics -To Institution AstraZeneca, AstraZeneca/ Daiichi Sankyo, Pfizer, Regeneron/Sanofi, Boehringer Ingelheim, Takeda, Arcus Biosciences, Gilead Sciences, Novocure, AbbVie AstraZeneca	Research Funding from Ineligible Companies Consultant Speaker	Faculty
Koichi Goto	Amgen Inc., Amgen K.K., DAIICHI SANKYO Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd., iTeos Therapeutics Inc., Janssen Pharmaceutical K.K., SYNEOS HEALTH CLINICAL K.K., Pharma Mar, S.A., Bayer Amgen Inc., Amgen K.K., Amgen Astellas BioPharma K.K., AstraZeneca K.K., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., Blueprint Medicines Corporation., Chugai Pharmaceutical Co., Ltd., Craif Inc., DAIICHI SANKYO Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Haihe Biopharma Co., Ltd., Ignyta,Inc., Janssen Pharmaceutical K.K., KISSEI PHARMACEUTICAL CO., LTD., Kyowa Kirin Co., Ltd., Life Technologies Japan Ltd., Loxo Oncology, Inc., LSI Medience Corporation., MEDICAL& BIOLOGICAL LABORATORIES CO., LTD., Merck Biopharma Co., Ltd., Merus N.V., MSD K.K., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Pfizer R&D Japan G.K., Precision Medicine Asia Co., Ltd., RIKEN GENESIS CO., LTD., Sumitomo Pharma Co., Ltd., Spectrum Pharmaceuticals, Inc., Sysmex Corporation., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Turning Point Therapeutics,Inc., Xcoo, Inc., AbbVie GK, AnHeart Amgen K.K., Amoy Diagnosties Co.,Ltd., AstraZeneca K.K., Bayer U.S., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., DAIICHI SANKYO Co., Ltd., Eisai	1. Advisory Board 2. Research Funding from Ineligible Companies 3. Speakers Bureau	Faculty
Rina Hui	Amgen, AstraZeneca, MSD, Eli Lilly, Janssen, Takeda, Zai Lab AstraZeneca, MSD, Daiichi Sankyp, Johnson & Johnson MSD	Advisor Speaker Reseacher/Investigator	Faculty
Puneeth Iyengar	Incyte AstraZeneca, Johnson & Johnson	Research Funding to Institution (Paid to Institution) Advisor	Faculty
Christian Rolfo	Intellisphere, MedStar, BMS, Novartis, Invitae, EMD Serono, AstraZeneca, Roche, Guardant Health, Pfizer	Consultant	Co-Chair/Reviewer
Benjamin Solomon	AstraZeneca, Roche, Pfizer, Amgen, D3Bio, GSK, BMS, MSD, Janssen AstraZenca, Roche, Pfizer	Advisor Speaker	Faculty
Junko Tanizaki	AstraZeneca K.K., AbbVie GK, Chugai Pharmaceutical Co. AstraZeneca, Boehringer Japan Inc., Bristol-Myers Squibb Co Ltd, Chugai Pharmaceutical Co, Daiichi Sankyo Co., Ltd., Eli Lilly Japan, Janssen Pharmaceutical, MSD, Ono Pharmaceutical Co. Ltd, Pfizer Japan Inc. Takeda Pharmaceuticals, Taiho Pharmaceutical Co. Ltd	Advisor Speaker	Faculty
Ross Soo	AbbVie, Amgen, AnHeart, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, GSK, J INTS BIO, Janssen, Lily, Merck, Merck Serono, Novartis, Pfizer, Puma, Roche, Sanofi, Taiho, Takeda, Thermo Fisher, Yuhan AstraZeneca, Boehringer Ingelheim, Pfizer Chugai	Advisory Board Research Funding from Ineligible Companies Speaker	Co-Chair/Reviewer
Yasushi Yatabe	Merk Biopharma, Chugai Pharma, Konica-Minolta REALM, Fisher Science, Invitae/Archer AstraZeneca, MSD, AbbVie, Novartis, Amgen, ArcherDx, Daiichi-Sankyo, Janssen Pharmaceuticals, Chugai-Pharma MSD, Chugai-Pharma, AstraZeneca, Merk Biopharma, Novartis, Amgen, Daiichi-Sankyo, AbbVie	Research Funding from Ineligible Companies Advisor Speaker	Faculty

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Study of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationships to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the live and enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Associates
The National Commission on Certification of Physician Associates (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Countries that accept ACCME-accredited continuing medical education (CME):

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians.

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.

Study the educational content online or print it out, if applicable.

Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.

Complete the activity evaluation to provide feedback for future programming and receive credit.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need assistance with this activity, please email: education@iaslc.org.